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Diffusion tensor imaging (DTI) metrics such as fractional anisotropy (FA) and mean diffu-
sivity (MD) have been proposed as clinical trial markers of cerebral small vessel disease
(SVD) due to their associations with outcomes such as cognition. However, studies inves-
tigating this have been predominantly single-centre. As clinical trials are likely to be multi-
site, further studies are required to determine whether associations with cognition of similar
strengths can be detected in a multicentre setting. One hundred and nine patients (mean
age =68 years) with symptomatic lacunar infarction and confluent white matter hyperinten-
sities (WMH) on MRI was recruited across six sites as part of the PRESERVE DTI substudy.
After handling missing data, 3T-MRI scanning was available from five sites on five scanner
models (Siemens and Philips), alongside neuropsychological and quality of life (QoL) as-
sessments. FA median and MD peak height were extracted from DTI histogram analysis.
Multiple linear regressions were performed, including normalized brain volume, WMH lesion
load, and n◦ lacunes as covariates, to investigate the association of FA and MD with cog-
nition and QoL. DTI metrics from all white matter were significantly associated with global
cognition (standardized β =0.268), mental flexibility (β =0.306), verbal fluency (β =0.376),
and Montreal Cognitive Assessment (MoCA) (β =0.273). The magnitudes of these associ-
ations were comparable with those previously reported from single-centre studies found in
a systematic literature review. In this multicentre study, we confirmed associations between
DTI parameters and cognition, which were similar in strength to those found in previous
single-centre studies. The present study supports the use of DTI metrics as biomarkers of
disease progression in multicentre studies.
Introduction
Cerebral small vessel disease (SVD) causes a quarter of all ischaemic strokes, is the most common
pathology underlying vascular cognitive impairment and dementia [1] and contributes to the sever-
ity of Alzheimer’s disease [2]. SVD affects the small vessels of the brain and results in a number of
characteristic radiological appearances best seen on MRI, including lacunar infarcts, T2-white matter
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hyperintensities (WMH), cerebral microbleeds, and brain atrophy [3,4]. In terms of symptoms, cognitive impairment
may be the most debilitating [5], with SVD characteristically associated with early deficits in executive function and
processing speed, while episodic memory is relatively spared [1,2,6-9].
Despite the public health importance of SVD, there are few specific treatments [10]. Furthermore, evaluating treat-
ments represent a major challenge due to the variable rate of cognitive decline, which can be slow in many patients,
but occurs rapidly with progression to dementia in a subset. While cognitive testing plays a central role in identifying
the presence of cognitive impairment, it has proved to be relatively insensitive to longitudinal change [11]. This has
led to the suggestion that MRI might represent a useful surrogate marker to monitor disease progression and evaluate
the efficacy of therapeutic interventions in smaller number of patients prior to larger phase III trials [3,12].
Diffusion tensor imaging (DTI) has been shown to be particularly sensitive to white matter damage in SVD. Ab-
normalities have been shown not only within T2-WMH but also in apparently ‘normal appearing white matter’ [13],
and these changes correlate better with cognition than WMH lesion volume [8]. In single-centre studies, change in
DTI could be detected in SVD patients over follow-up periods of 1–3 years [14,15]. This has led to the suggestion
that DTI might provide a useful surrogate marker and power calculations for phase II trials based on the rate of DTI
change seen in these papers, which show that its use may allow evaluation of therapeutic interventions with much
smaller sample sizes than if cognitive function was used as an outcome measure [11]. However, studies conducted to
date have been single-centre [12,15,16]. Most therapeutic trials are likely to be multicentre and involve acquisition of
DTI across different sites. As image acquisition will be on different scanners, this may present challenges [17]. It is
important to assess whether DTI is feasible in a clinical trial setting, and whether similar associations between MRI
parameters and clinical and cognitive variables can be detected in the multicentre setting. One way of assessing this
is to determine whether the strength of association between DTI and cognition in multicentre studies is similar to
that previously reported in single-centre studies.
To evaluate this, we determined the association between DTI parameters and cognition in the baseline data of a
multicentre trial.
Methods
PRESERVE study
The PRESERVE study (‘How intensively should we treat blood PRESsure in established cERebral small VEssel dis-
ease?’) is a multicentre randomized controlled trial comparing a strategy of intensive compared with standard treat-
ment of blood pressure on cognitive function over a 2-year follow-up period. Nested within the overall study is a DTI
substudy in which patients additionally undergo multimodal MRI including DTI at baseline and at the end of the
2-year follow-up period. The baseline data from these individuals are presented in the present paper.
Study population
Inclusion criteria were: a clinical lacunar stroke with an anatomically corresponding lacunar infarct on MRI, in addi-
tion to confluent WMH graded as2 on the Fazekas scale [18]. Patients were at least 40 years old with hypertension
defined as either a systolic blood pressure >140 mmHg, or a systolic blood pressure between 125–140 mmHg while
on antihypertensive treatment. Exclusion criteria were: a known single gene disorder causing SVD (e.g. CADASIL),
symptomatic carotid stenosis or vertebral stenosis>50% , cortical infarction>2 cm diameter, diagnosis of dementia,
life expectancy of less than 2 years, symptomatic postural hypotension, women with childbearing potential and any
inability to fulfil study data collection. All patients gave informed written consents. The study was approved by the
Harrow National Research Ethics Service committee (”REC” number: 11/LO/0458) and is registered with the U.K.
Clinical Research Network (CRN number: 10962).
One hundred and nine patients from six sites consented to participate in the PRESERVE DTI substudy. The site
sample sizes are as follows: site 1 (n=48), site 2 (n=29), site 3 (n=14), site 4 (n=11), site 5 (n=6), site 6 (n=1).
Participants underwent baseline testing at least 3 months post-stroke.
Clinical assessments
A stroke physician or vascular neurologist examined all the participants. Cerebrovascular risk factors including a
history of previous stroke, hypercholesterolaemia, diabetes, smoking (current and history), angina, myocardial in-
farction, coronary artery bypass grafts (CABGs) or coronary angioplasty were recorded.
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Neuropsychological assessment
Cognitive testing
Assessment was performed by a neuropsychologist and occurred on the same day as MRI scanning or as close to the
scan as possible. A cognitive test battery was used which included tests sensitive to the characteristic impairments in
processing speed and executive function associatedwith SVD [2], with additional testing ofmemory. This included for
Processing speed theDigit Symbol Coding test (DSC) [19], and for executive functioning the Trail Making Test (TMT,
[20]) to measure mental flexibility and a phonemic verbal fluency task (”FAS”) [21] and a semantic verbal fluency
task (animals) [22] to measure verbal generativity.Memory was measured using the Rey Auditory Verbal Learning
Test (RAVLT, [23]). Premorbid IQ was estimated using the restandardized National Adult Reading Test (NART-R,
[24]) and additional screening for cognitive impairment was conducted using the Montreal Cognitive Assessment
(MoCA, [25]).
In addition, following assessments of disability and quality of life (QoL) were performed; the stroke-specific QoL
assessment (SSQoL) [26] and the EuroQoL [27].
Performance across neuropsychological tests was made comparable by transforming raw scores into z-scores using
the best available age-scaled normative data (DSC; [19], TMT; [28], letter fluency; [21], animal fluency; [22], RAVLT;
[28]). Tasks were grouped into four key domains (Processing speed: Wechsler Adult Intelligence Scale coding to-
tal correct, TMT-A time to complete, Mental flexibility: TMT-B time to complete, Verbal fluency: total correct for
‘FAS’ letter fluency and animal fluency and Verbal memory: RAVLT ‘immediate’ and ‘delayed’ recall). Individual task
z-scores were averaged across these groupings to create overall domain scores, while all domain scores were averaged
to create aGlobal cognition domain. SSQoL (total score), EuroQoL (‘healthstate’ rating) and the MoCA (total score)
were analysed individually using raw scores.
Where data were missing due to a subject being unable to complete a task, the lowest available z-score was given;
this applied to 15 individual tasks, across 13 participants (11.9% of the sample size). If data were missing for any
other reasons then the domain scores were calculated without that task; this applied to three participants (2.8% of the
sample size).
MRI acquisition
The aim was to test a study design for which MRI data were acquired using clinical scanners in different sites from
different manufacturers. Within the six centres, eight 3-Tesla MR scanners were used (three Philips Achieva TX, one
Philips Achieva, one Philips Ingenia, one Siemens Verio, one Siemens Prisma, one Siemens Magnetom Prisma fit).
MRI acquisition included 3D T1-weighted (T1W), and DTI, T2*-weighted (T2*W) and Fluid-attenuated Inversion
Recovery (FLAIR) scans for each participant. A rigorous quality control was implemented to ensure sequence acqui-
sition parameters were as standardized as possible. T1W scans were acquired at 1-mm3 isotropic voxel resolution and
TR and TE were optimized to ensure comparable T1 weighting and tissue contrast across sites. DTI scans (2-mm3
isotropic voxel resolution) had similar TEs and long TRs to avoid T1 relaxation effects. In addition to the b =0 s
mm−2 acquisitions, all DTI acquisition included 32 equally spaced, non-collinear diffusion gradient directions (b
=1000 s mm−2) to ensure identical angular resolution and noise characteristics. T2*W sequences were TE matched
and kept a similar TR to ensure comparable weighting. FLAIR sequences had identical inversion times and were also
TE matched with long enough TRs to ensure no T1 weighting occurred. Resolution for T2*W and FLAIR sequences
varied between sites; Supplementary Table S1 gives an overview of the exact scanner and sequence details per site.
MRI data analysis
In addition to DTI, measures describing WMH, lacunes and brain volume are frequently investigated as potential
markers of SVD [8,12,29-31]. In the present study, these were analysed as a comparison with DTI.
WMH
WMH were defined as areas of increased signal on FLAIR images (excluding the rims of cavitated lacunes) and
segmented by a single trained rater (I.D.C.) using a semi-automated, contouring technique in Jim image analysis
software version 7.0 5 (Xinapse Systems Limited, http://www.xinapse.com/j-im-7-software/). Whole brain WMH
lesions maps were generated and a WMH lesion load score was calculated as the percentage of WMH lesion volume
against whole brain volume. To assess intra- and inter-rater reliability, a test set of ten FLAIR scans (from a previous
study in SVD) with varying degrees of WMH was used. In a randomized, blinded setting FLAIR images were each
marked twice by I.D.C. and once by a second experienced rater (D.T.). The intraclass correlation coefficient [32] was
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calculated to assess inter-rater reliability (I.D.C. compared with D.T.) and intrarater reliability providing coefficients
of 0.988 and 0.998 respectively.
Lacunes
Lacunes were defined as cerebrospinal fluid (CSF)-filled cavities at least 3mm in diameter. Additional features such as
T2-hyperintense rims, shape and location were also considered to differentiate lacunes from similar imaging features
such as perivascular spaces. The same single rater (I.D.C.) identified lacunes after training by a consultant neurora-
diologist using a combination of T1W, T2*W and FLAIR scans.
Brain volume
T1W scans were intensity non-uniformity corrected using ‘N4ITK’ [33] and segmented into grey matter (GM), white
matter (WM) and CSF tissue probability maps (TPM) using SPM12b (Statistical Parametric Mapping (SPM), http:
//www.fil.ion.ucl.ac.uk/spm/ [34]). Brain volume in native space was calculated from the soft segmentation of the
GM and WM TPMs.
To obtain brain volume measures sensitive to atrophy, ”SIENAX” ( [35], a part of FMRIB Software Library (FSL),
https://fsl.fmrib.ox.ac.uk/fsl [36]) was applied to T1W scans giving a scaling factor that describes the variation of
brain size relative to the skull size. The native space brain volumes were multiplied by this scaling factor to provide
normalized brain volumes (NBVs). To minimize the tissue misclassification of WMH as GM, the (normalized) vol-
ume of any GM which occurred within WMH was subtracted from the GM volume and added to the WM volume.
Finally, whole NBV was calculated by adding GM and WM NBVs together.
DTI histogram analysis
FSL software (”FDT”; FMRIB’s Diffusion Toolbox, http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FDT) was used for DTI pre-
processing. Briefly, DTI scans were eddy current corrected with eddy correct using the first acquired b =0 s mm−2
image as the reference. A binary brain mask in DTI space was calculated for each subject using ”BET” on the same
b =0 acquisition. Fractional anisotropy (FA) and mean diffusivity (MD) maps were then calculated from these data
using ”DTIFIT”. Voxels with MD values above 0.0026 mm2s−1 were removed from analyses in case they had been
misclassified as CSF voxels by application of a diffusivity threshold. Likewise, spurious voxels with FA >1 were also
removed. For each participant, FMRIB Linear Image Registration Tool (FLIRT, [37], using the normalized mutual in-
formation cost function in FSL) was used to register the FLAIR to the T1W image and the T1W to the b0 image (the
average of all the b=0 s mm−2 images in the DTI sequence). These affine transformationmatrices were concatenated
to create a third FLAIR-to-DTI transformation. TPMs and WMH lesion masks were registered into DTI space using
the T1W-to-DTI (trilinear interpolation) and FLAIR-to-DTI (nearest neighbour interpolation) transforms for TPMs
and binary WMH lesion masks respectively.
A hard segmentation method was applied to generate maps of tissue classes. This was achieved by voxelwise com-
parison of the GM, WM and CSF TPMs, with each voxel being assigned to the highest probability tissue class. The
WMH lesion masks were then added with these lesion voxels being automatically assigned to WMH. Finally, mask
images of normal appearing white matter (NAWM) and all white matter (WM) were generated from the hard seg-
mentation map.
Histogram analysis was performed on FA and MD maps in both NAWM and WM. Normalized histograms with
1000 bins (FA range: 0–1, bin width: 0.001; MD range: 0–4 mm2s−1 × 10−3, bin width: 0.004 mm2s−1 × 10−3) were
computed and median, peak height and peak value were extracted from these for both FA and MD. These metrics
were chosen as summary measures as FA and MD are non-normally distributed in WM.
Statistical analyses
All analyses were performed using IBM SPSS statistics version 23 (IBM Corp. Released 2013. IBM SPSS Statistics for
Windows. Armonk, NY: IBM Corp, http://www.ibm.com/analytics/us/en/technology/spss/).
One measure for each MD and FA was chosen for the main study analyses. MD (normalized) peak height and
FA median were picked due to previous studies which have shown these to be correlated with cognition [8,14] and
sensitive to change in WM microstructure in SVD [11,15].
To compare MRI with cognitive parameters, ‘Simple’ and ‘Complex’ model linear regressions were conducted. This
pipeline was structured as a method of selecting the most appropriate MRI measure per type (e.g. one brain tissue
volumemeasurement orMD/FAhistogramparameter forDTI) so that contributions ofMRImetrics couldbe assessed
together, while avoiding issues of multicollinearity. Thus, in Simple models, the association of NBV, WMH lesion
load, lacunes and histogram parameters (from NAWM and WM) were separately investigated against each outcome
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measure (cognitive domains,QoL and MoCA). As there weremultipleNBV and DTI variables, themost significant of
each type (or if P-value was the same, the one with the largest β-value) per outcome measure, was selected and used
in the Complex model. Here, NBV, WMH lesion load, n◦ lacunes and DTI measures were included together to assess
their contributions relative to each other. Separate Complex models were performed for each outcome measure, in
WM and NAWM. These models controlled for confounding effects of age, gender, premorbid IQ and were stratified
by study site. Residuals were inspected for normality for all regression analyses while variance inflation factors were
also calculated for the Complex models to assess multicollinearity.
Further analyses compared DTI and outcome variables between sites and repeated some Complex model analyses
using site-specific data. These are detailed in the Supplementary material.
Systematic review
To allow comparison of the results with previous single-centre studies, a systematic review of previous literature was
conducted on PubMed (https://www.ncbi.nlm.nih.gov/pubmed/) using as search terms ‘cerebral small vessel disease
diffusion tensor imaging’, ‘white matter hyperintensities diffusion tensor imaging’ and ‘leukoaraiosis diffusion tensor
imaging’ on 16th March, 2017. Criteria for inclusion were: (i) studies of sporadic SVD population (i.e. monogenic
causes of SVD such as CADASIL were not included), (ii) studies investigating the relationship between DTI metrics
and cognitive performance, (iii) studies investigating the cognitive domains analysed in the current study, (iv) analysis
controlling at least one other confounding MRI measure, (v) results involved reporting of standardized β-values or
partial correlation coefficients. Where a paper reported multiple associations against the same cognitive outcome, the
strongest (i.e. largest β-value) was included. In cases where a study had published multiple papers based on the same
participant data, the one which used the most similar metrics to those in the presented study was chosen.
Results
Proﬁle of participant variables
Missing data
Due to the low sample size (n=1), site 6 was excluded from all statistical analyses. An additional six participants were
excluded from analysis due to MRI data acquisition problems (two cases from site 1 due to excessive motion artefacts
and corrupted data acquisition and four cases from site 4 where not all imaging sequences were acquired and some
data were corrupted). Sample size was further reduced by incomplete cognitive data. Verbal fluency data was absent
for one participant, Verbal memory and NART in another and (only) NART in third. Sample size was therefore re-
duced by further three for Verbal fluency comparisons, and by two for all other comparisons.Consequently, complete
DTI data were available in 102 participants, while sample size formain statistical analyses was n=99 for testingVerbal
fluency or n=100 for all other outcome measures.
Demographics
Demographics, risk factors and clinical features are shown in Table 1.
All entry MRI scans were reviewed centrally by a consultant neurologist. All cases fitted the MRI inclusion criteria
except two which had WMH graded on the Fazekas scale of<2. Both were included in analysis as they had multiple
lacunes consistent with severe SVD.
Cognition
The cognitive profile of the participants is shown in Figure 1. All five cognitive domains were significantly impaired
compared with control performance levels (P0.001 in all cases except for Verbal fluency where P0.05).
MoCA, QoL and MRI results
Mean values for MoCA, SSQoL, EuroQoL and MRI parameters are shown in Table 2. Qualitative comparison of
histogram measures between the WM and NAWM tissue classes showed that the inclusion of WMH in the WM
lowered the (normalized) peak height of FA and MD, increased the peak value and median of MD, and decreased the
peak value and median of FA.
Relationship between MR variables and cognition
Simple model analyses
Full findings are shown in Table 3. FAmedian and MD peak height (inWM andNAWM) were significantly associated
with all outcome measures, except for NAWM MD peak height with Processing Speed, both NAWM measures with
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Table 1 Baseline characteristics of the study population
Demographic variables Mean (S.D.)/number (%)
Age, mean (S.D.) years 68.2 (9.07)
Male, n (%) 64 (58.7%)
Premorbid IQ 115.8 (8.12)
MoCA <26 54 (49.5%)
Systolic blood pressure (mmHg) 150 (13)
Diastolic blood pressure (mmHg) 85 (12)
Previous stroke, n (%) 21 (19.3%)
Hypercholesterolaemia, n (%) 84 (77.1%)
Diabetes, n (%) 24 (22.0%)
Current smokers, n (%) 16 (14.7%)
Former smokers, n (%) 40 (37.7%)
Angina, n (%) 7 (6.4%)
Myocardial infarction, CABG or coronary angioplasty, n (%) 6 (5.5%)
Peripheral vascular disease, n (%) 2 (1.9%)
History of depression, n (%) 20 (18.3%)
Other missing data not previously reported; former smoker =3; peripheral vascular disease =1.
Figure 1. Cognitive proﬁle of the SVD patient group.
This figure shows average, age-matched z-scores for cognitive indices. Error bars represent +− 1 S.E.M. Index score significantly different
from zero: ** P 0.001, * P0.005.
SSQoL and all DTI measures with Verbal memory. Median FA held stronger associations than MD peak height in all
cases except for EuroQoL in (all) WM. The directions of these relationships demonstrate that higher median FA and
MD peak height were associatedwith better cognition orQoL in both tissue classes. Therewere nomarked differences
between the patterns or strengths of associations for DTI measures taken from within NAWM or the whole of the
WM. Whole NBV held stronger associations than GM or WM NBV in all cases except EuroQoL, where WM was
strongest.
Complex model analyses
‘Complex models’ were performed to determine which MRI variables were independently associated with the out-
come measures and results are shown in Table 4. The variance inflation factors of all models were smaller than three
and deemed acceptable. Median FA was significantly associated with Global cognition, Mental flexibility, Verbal flu-
ency and MoCA in both the tissue classes. No other comparisons with DTI metrics reached significance. Considering
the significant associations, the effective sizes of the WM comparisons (as indicated by the β-value) were always de-
scriptively greater than the NAWM counterpart.
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Table 2 Mean scores for key individual variables using all available data
Variables Mean (S.D.), range
Cognitive/QoL variables
MoCA 24.9 (3.5), 11–30
SSQoL 190.6 (32.8), 93–244
EuroQoL 69.3 (19.1), 0–100
MRI variables
NBV (whole brain, ml) 1355.84 (107.70)
GM normalized volume (ml) 714.49 (73.48)
WM normalized volume (ml) 641.35 (70.39)
WMH volume (ml) 34.74 (22.27)
WMH lesion load (% brain) 3.41 (2.22)
Lacunes (number) 4.41 (4.73)
FA height × 10−3 (NAWM/WM) 3.27 (0.26)/3.24 (0.25)
MD height × 10−2 (NAWM/WM) 1.42 (0.21)/1.33 (0.23)
FA value (NAWM/WM) 0.320 (0.042)/0.311 (0.047)
MD value mm2s−1 × 10−3 (NAWM/WM) 0.761 (0.040)/0.762 (0.040)
FA median (NAWM/WM) 0.342 (0.026)/0.335 (0.028)
MD median mm2s−1 × 10−3 (NAWM/WM) 0.774 (0.039)/0.787 (0.044)
Table 3 Results from linear regression ‘Simple model’ analyses
MR variables Global cog. Proc. speed Mental ﬂex.
Verbal
ﬂuency
Verbal
memory MoCA SSQoL EuroQoL
Volume
measures
Whole NBV 0.330 (0.003) 0.361 (0.002) 0.286 (0.016) 0.171 (0.153) 0.245 (0.041) 0.421
(0.001)
0.273 (0.036) 0.200 (0.115)
Grey NBV 0.167 (0.109) 0.109 (0.321) 0.111 (0.312) 0.147 (0.177) 0.177 (0.109) 0.339 (0.001) 0.084 (0.485) –0.016 (0.888)
White NBV 0 .199 (0.036) 0.283 (0.004) 0.202 (0.043) 0.049 (0.627) 0.101 (0.320) 0.142 (0.150) 0.213 (0.051) 0 .225 (0.034)
WMH measure Lesion load –0.288 (0.001) –0.312 (0.001) –0.245 (0.009) –0.240 (0.011) –0.132 (0. 170
)
–0.196 0.035) –0.249 (0.015) –0.248 (0.013)
Lacune
measure
N◦ lacunes –0.357
(0.001)
–0.389
(0.001)
–0.268 (0.006) –0.286 (0.003) –0.233 (0.018) –0.333
(0.001)
–0.323 (0.002) –0.195 (0. 062 )
NAWM DTI
measures
FA median 0. 352
(0.001)
0.247 (0.009) 0.338
(0.001)
0.374
(0.001)
0.167 (0.081) 0.332
(0.001)
0.196 (0.058) 0.253 (0.011)
MD peak
height
0.267 (0.005) 0.186 (0.063) 0.241 (0.016) 0.275 (0.006) 0.160 (0.115) 0.262 (0.007) 0.170 (0.121) 0.244 (0.021)
WM DTI
measures
FA Median 0.371
(0.001)
0.282 (0.002) 0.354
(0.001)
0.375
(0.001)
0.174 (0.067) 0.329
(0.001)
0.213 (0.037) 0.267 (0.007)
MD peak
height
0.303 (0.001) 0 .247 (0.011) 0.273 (0.005) 0.293 (0.003) 0.162 (0.101) 0.262 (0.006) 0.218 (0.042) 0.291 (0.005)
All numbers are standardized β-values (P-values). Signiﬁcant relationships are shown in bold while the most strongly associated MR variable per outcome
per category is underlined.
The number of lacunes was independently and significantly associated with Global cognition, Processing speed,
MoCA and SSQoL in both tissue class models. NBV only maintained a significant association with MoCA and Euro-
QoL (in both tissue class models). WMH lesion load was no longer significantly related to any outcome measures.
Systematic review: comparison of strength of associations between DTI
and cognition with that from previous studies
The search terms identified 230 papers, and after reading their abstracts, 37 selected for review. An additional five
papers were identified from reference lists. Eight of these 42 papers met inclusion criteria [8,12,29-31,38-40]. Sup-
plementary Table S2 details these papers and includes key findings from each study. Of note, one of these [39] is a
multicentre study across three sites using identical 1.5T scanners and acquisition sequences, with MoCA and MMSE
as cognitive measures.
Two of these papers reported 95% confidence intervals (CI) with their β-values for associations between DTI
metrics and cognition [12,38]. Comparing the magnitude of the DTI-based β-values (ignoring direction, as this will
be influencedby the specificDTIparameter used, whichdiffers betweenpapers) from the presented study for the same
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Table 4 Results from linear regression ‘Complex model’ analyses
Tissue
class model MR variable Global cog. Proc. speed Mental ﬂex.
Verbal
ﬂuency
Verbal
mem. MOCA SSQoL EuroQoL
NAWM Whole NBV 0.134 (0.227) 0.197 (0.098) 0.112 (0.363) –0.041 (0.735) 0.163 (0.213) 0.284 (0.014) 0.137 (0.323) –
[–0.085 :
0.353]
[–0.037 :
0.432]
[–0.131 :
0.356]
[–0.280 :
0.198]
[–0.095 :
0.422]
[0.058 :
0.509]
[–0.137 :
0.410]
WM NBV – – – – – – – 0.230 (0.030)
[0.023 : 0.437]
WMH lesion
load
–0.029 (0.775) –0.126 (0.246) -0.009 (0.938) 0.006 (0.954) 0.033 (0.784) 0.116 (0.270) –0.100 (0.428) –0.144 (0.315)
[–0.230 :
0.172]
[–0.341 :
0.089]
[–0.232 :
0.215]
[–0.212 :
0.225]
[–0.204 :
0.270]
[–0.091 :
0.323]
[–0.351 :
0.150]
[–0.354 : 0.125]
N◦ lacunes –0.251 (0.006) –0.287 (0.004) –0.166 (0.099) –0.192 (0.057) –0.186 (0.082) –0.247 (0.009) –0.245 (0.031) –0.047 (0.672)
[–0.429 :
–0.072]
[–0.477 :
0.096]
[–0.365 :
0.032]
[–0.390 :
0.006]
[–0.397 :
0.024]
[–0.431 :
–0.063]
[–0.467 :
–0.022]
[–0.266 : 0.172]
FA median 0.227 (0.023) 0.038 (0.717) 0.253 (0.022) 0.333 (0.002) 0.085 (0.463) 0.244 (0.018) 0.032 (0.796) 0.196 (0.099)
[0.032 :
0.421]
[–0.170 :
0.247]
[0.037 :
0.470]
[0.121 :
0.546]
[–0.145 :
0.315]
[0.043 :
0.445]
[–0.211 :
0.275]
[–0.037 : 0.428]
MD peak
height
– – – – – – – –
Model sig.
(P-value, adj.
R2)
<0.001, 0.429 <0.001, 0.334 <0.001, 0.292 <0.001, 0.317 0.001, 0.202 <0.001, 0.392 0.029, 0.108 0.004, 0.164
WM Whole NBV 0.131 (0.236) 0.194 (0.103) 0.107 (0.380) –0.041 (0.730) 0.162 (0.215) 0.284 (0.014) 0.139 (0.316) –
[–0.087 :
0.349]
[–0.040 :
0.428]
[–0.135 :
0.350]
[0.280 : 0.197] [–0.096 :
0.421]
[0.058 :
0.509]
[–0.135 :
0.0412]
WM NBV – – – – – – – 0.225 (0.033)
[0.018 : 0.432]
WMH lesion
load
0.025 (0.882) –0.110 (0.359) 0.055 (0.655) 0.075 (0.536) 0.052 (0.693) 0.164 (0.155) –0.100 (0.474) –0.081 (0.545)
[–0.195 :
0.245]
[–0.346 :
0.127]
[–0.189 :
0.299]
[–0.165 :
0.315]
–0.209 : 0.313] [–0.063 :
0.392]
[–0.376 :
0.176]
[–0.347 : 0.184]
N◦ lacunes –0.248 (0.007) –0.285 (0.004) –0.163 (0.104) –0.190 (0.059) –0.186 (0.083) –0.245 (0.009) –0.245 (0.031) –0.047 (0.669)
[–0.425 :
–0.70]
[–0.476 :
–0.095]
[–0.360 :
0.034]
[–0.388 :
0.007]
[–0.396 :
0.025]
[–0.429 :
–0.062]
[–0.468 :
–0.023]
[–0.267 : 0.172]
FA median 0.268 (0.016) 0.058 (0.621) 0 .306 (0.013) 0.376 (0.002) 0.099 (0.445) 0 .273 (0.017) 0.026 (0.849) –
[0.052 :
0.484]
[–0.174 :
0.290]
[0.066 :
0.546]
[0.140 :
0.612]
[–0.157 :
0.355]
[0.049 :
0.497]
[–0.245 :
0.297]
MD peak
height
– – – – – – – 0.209 (0.112)
[–0.050 : 0.468]
Model sig.
(P-value, Adj.
R2)
<0.001, 0.433 <0.001 0.345 <0.001, 0.299 <0.001, 0.319 0.001, 0.202 <0.001, 0.392 0.029, 0.108 0.004, 0.162
All numbers are standardized β-values (P-values) (95% standardized β conﬁdence interval (CI)), with overall model signiﬁcance being given on the bottom
row. Models are separated into those which test NAWM and WM metrics horizontally. Signiﬁcant associations are shown in bold.
cognitive domain shows that these fell within or were higher than these previously reported CIs for Global cognition
(ourβ=0.268, previousCIs= –0.22 to –0.06 [12] and –0.38–0.02 [38]) Executive functioning (i.e.Mental flexibility;
ourβ=0.306, previous CIs= –0.16 to –0.06 [12] and 0.05–0.39 [38]), Verbal fluency (ourβ=0.376, previous CIs=
–0.21 to –0.02 [12]) and Verbal Memory (our β=0.099, previous CIs = –0.28 to –0.06 [12]). Only the presented β
for Processing speed was lower than a previously reported CI (but only in one of these papers; ourβ=0.058, previous
CIs= –0.24 to –0.06 [12] and –0.33 to 0.06 [38]). Conversely, previously reported β-values from all the eight papers
fell within the CIs found in the presented analyses in all instances except for one case of Verbal memory being greater
than our CI (previous β = –0.86 [31], our CI = –0.157 to 0.355) and one case of Verbal fluency being lower than
our CI (previous β= -–.11 [12], our CI = 0.140–0.612).
Site-speciﬁc ﬁndings
These analyses are reported in full in the Supplementary material.
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Figure 2. A scatterplot showing the relationship between WM FA median and Mental ﬂexibility, stratiﬁed by study site.
In addition to individual site regression lines, the regression line for the total is also included with accompanying 95%CI limits (black, dashed
line).
In order to assess any variation across individual sites, analyses were conducted on data from each site individually.
FA median and MD peak height of each site were compared by one-way ANOVA, which returned a non-significant
finding for each (FA: P=0.424, MD: P=0.148). Comparison of all outcome measures (i.e. cognitive domains, MoCA
and QoL scales) between sites by one-way ANOVA and Kruskal–Wallis also showed no significant findings (P-value
range: 0.192–0.827).
‘Complex model’ analyses were also repeated at sites 1, 2 and 3 individually. These were repeated in cases where a
DTI metric had been shown to have a significant relationship with a cognitive domain in the main analyses. These
relationships were further visualized by scatterplot in all sites, with the 95% CI around the total regression line also
included for comparison. Complex model results showed sites 1 and 2 to have β-values which were within or higher
than the 95% CI limits for the same comparison in the main analyses. While this was also true for site 3 in the
Global cognitionmodel, the Mental flexibility and Verbal fluencymodels gave a lowerβ-value than the CI limits. The
scatterplot with the ‘weakest’ (i.e. flattest) individual site fit is included here as Figure 2. This shows the relationship
between WM FA median and Mental flexibility, with a weak fit for site 4 (but not site 3) in that its line falls outside
the total CI limits in a manner showing it to be flatter. Supplementary Figures S1 and S2 repeat this scatterplot for
Global cognition and Verbal fluency comparisons and likewise indicate site 3 (but not site 4) to have a weak fit in
each. All other sites show either good fits (i.e. fall completely within the CI limits; see site 1 in Figure 2) or ‘strong’
ones (i.e. fall outside the total CI limits in a manner showing them to have steeper slopes; see sites 2, 3 and 5 in Figure
2). This suggests that the majority of sites do contribute to the main study findings. It is possible that individual cases
of small Complex model β-values, and unusually ‘weak’/‘strong’ scatterplot fits are due to lack of power from low
sample sizes.
Discussion
In this analysis of baseline data from a multicentre clinical trial of SVD, we found associations between DTI metrics
and cognition of a similar magnitude to those reported in previous single-centre studies. This provides support for
the use of DTI measures as surrogate markers in clinical trials of SVD.
We found that both DTI markers and lacunar infarct count were independently associated with Global cognition
and MoCA results. Additionally, DTI markers were independently associated with Mental flexibility and Verbal flu-
ency, and lacunes with Processing speed and SSQoL. In contrast, we found no independent associations between
WMH lesion load and cognition and only two for brain volume (with MoCA and EuroQoL). This is in-line with
most previous literature from single-centre studies, which have found weak or absent associations between WMH
and cognition in patients with severe symptomatic SVD [8,29,39]. However, it has been previously shown, as we
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also have, that the presence and number of lacunar infarcts [8,38] and the extent of diffuse WM damage assessed
on DTI [8,12,29,31,38,39], are the strongest predictors of cognitive functioning. Furthermore, both have been shown
to predict risk of dementia in longitudinal studies [41,42], while lacunes and the apparent diffusion coefficient (a
diffusion-weighted imaging measure highly similar to MD) have also been shown to predict future cognitive decline
[43,44]. Number of lacunes was chosen in the present study instead of lacune volume as it is a more practical measure
to obtain in a clinical setting, and similar associations with cognitive performance have been found between these in
a comparable severe SVD population [45].
Clinical trials of new agents in SVD will need to be multicentre and if MRI is to be used as a surrogate marker,
it is important to evaluate how the different markers perform in a multicentre setting. While research in other neu-
rological disorders such as Parkinson’s [46] and Huntington’s [47] disease have shown that DTI markers of disease
can be successfully applied in a mutlicentre study, there have been few studies addressing this issue in SVD. The use
of multiple scanners, possibly from different manufacturers, is likely to add noise and may diminish the statistical
sensitivity of these metrics.
PRESERVE is one of the first studies to use advanced MRI as a surrogate marker in SVD trials. In this setting, we
have shown that the magnitudes of associations between DTI and cognition are highly comparable with previous,
single-centre studies, further validating the use of these metrics in this context. Additionally, while WM and NAWM
DTI were always significantly associated with the same outcomes, the strengths of these associations was consistently
descriptively greater in WM models. This indicates the simpler process of obtaining a WM mask is at least equally
valid and may be more practical in a clinical setting. It should also be noted that previous research has indicated
through power calculations that DTI parameters could detect change with much smaller sample sizes than lacunes,
due to the frequency of new lacunes being relatively low [11]. This suggests thatDTImetricsmay be themost powerful
surrogate marker of the two.
Examination of individual site data did demonstrate some variation in the strength of associations between MR
parameters and cognition from different centres, but themajority of these effect sizes were within (or greater than) the
expected ranges asdetermined by 95% CIs forβ-values and regression slopes from themain analyses.DTImetrics and
cognition did not significantly differ between sites,meaning that it is likely that a lack of power due to a low site sample
size was a contributing factor to the instances where this was not the case. The similarity of DTI and cognitivemetrics
across sites also suggests good comparability between the centres involved in the present study. With respect to the
wider literature however, the authors do note that DTI metrics have sometimes been shown to differ in magnitude
between manufacturers, such as one paper where MD values were found to be systematically higher on Siemens
compared with Philips scanners (this would not affect peak height of MD as used in the presented study, but could
affect measures of MD centrality [48]). Another paper [49] examined reproducibility of whole brain MD peak height
between a 1.5T and a 3T Siemens scanner in a sample size of seven CADASIL patients, which achieved an intraclass
correlation coefficient of 0.752 (indicating ‘good’ reliability [50]). A further paper has found that scanner upgrades to
affect DTI after scanning CADASIL patients [51]. These findings show that caution should be used when combining
DTI data from different manufacturers or when takingmeasurements over time and future researchmay wish to take
this into account in analyses. These considerations also highlight the importance of conducting multicentre scanner
calibration and standardization of acquisition protocols prior to study commencement, as well as on-going quality
control checks during the study duration in multicentre research of this nature.
There were some limitations to the present study. There were variable sample sizes across sites, meaning the in-
fluence of some centres is much stronger than others on our findings. In particular, having a greater number of par-
ticipants scanned on non-Philips hardware would have provided more information about the comparability across
scanners. The lack of data on inter-scanner reproducibility is also limiting and would have been valuable in more
closely judging the sensitivity of these metrics across sites. It would also have been advantageous to acquire a field
map with the DTI protocol so that corrections for susceptibility induced distortions could have been made. However
registration to DTI space did appear good, so this is unlikely to have caused any major problems.
To conclude, in a multicentre study, we have shown that DTI metrics and lacune count correlate with cognition to
a similar degree to that found in single-centre studies. Our findings support the use of DTI as a surrogate marker of
SVD in multicentre studies.
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Clinical perspectives
• DTI metrics have been suggested as clinical trial markers of SVD, but studies investigating this
have been single-centre and as clinical trials are likely to be multicentre. We investigate the as-
sociations between these metrics and cognition in a multicentre clinical trial of SVD.
• In a cross-sectional analysis, significant associations were found between white matter DTI met-
rics and cognition; these were of a comparable magnitude with those previously reported in
single-centre studies.
• These findings support the use of DTI metrics as markers of SVD in multicentre clinical trials.
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